Ophir Asset Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,255,235
Closed -$18.4M 33
2025
Q3
$18.4M Buy
1,255,235
+34,312
+3% +$588K 2.27% 20
2025
Q2
$22.7M Buy
1,220,923
+59,584
+5% +$1.22M 3.61% 15
2025
Q1
$23M Sell
1,161,339
-180,457
-13% -$3.12M 4.02% 10
2024
Q4
$23M Buy
1,341,796
+578,722
+76% +$10.9M 3.43% 11
2024
Q3
$15.3M Sell
763,074
-1,068,256
-58% -$16.6M 2.35% 19
2024
Q2
$20.5M Sell
1,831,330
-1,597,987
-47% -$13.4M 3.63% 15
2024
Q1
$22.6M Buy
+3,429,317
New +$18.7M 3.97% 11

Other funds holding ADMA

Ophir Asset Management's ADMA Position: Q4 2025 in Review

Ophir Asset Management sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 1,255,235 shares — an estimated $18.4M sold.

Ophir Asset Management first reported a position in ADMA in Q1 2024 and held it in 7 quarters. The position peaked at $23M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Ophir Asset Management reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Ophir Asset Management sold 1,255,235 ADMA Biologics shares in Q4 2025, an estimated $18.4M.
  • Ophir Asset Management first reported a position in ADMA Biologics in Q1 2024 and held it in 7 quarters.
  • Ophir Asset Management's ADMA Biologics position peaked at $23M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Ophir Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.